Last updated on February 2019

Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C) ROS1 or ALK Gene Rearrangements (Fusions)


Brief description of study

This is an open-label, multicenter, global Phase 2 basket study of entrectinib (RXDX-101) for the treatment of patients with solid tumors that harbor an NTRK1/2/3, ROS1, or ALK gene fusion. Patients will be assigned to different baskets according to tumor type and gene fusion.

Clinical Study Identifier: NCT02568267

Contact Investigators or Research Sites near you

Start Over

Reference Study ID Number: GO40782 ...

The Chinese University of Hong Kong
Shatin, Hong Kong
  Connect »

Reference Study ID Number: GO40782 ...

Queen Elizabeth Hospital
Kowloon, Hong Kong
4.2miles
  Connect »

Reference Study ID Number: GO40782 ...

Hong Kong Integrated Oncology Centre
Hong Kong, Hong Kong
5.77miles
  Connect »

Reference Study ID Number: GO40782 ...

Princess Margaret Hospital
Hong Kong, Hong Kong
5.77miles
  Connect »

Reference Study ID Number: GO40782 ...

The University of Hong Kong
Hong Kong, Hong Kong
5.77miles
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.